Page 135 - Read Online

Page 2 of 3 Hershman. J Cancer Metastasis Treat 2022;8:3 https://dx.doi.org/10.20517/2394-4722.2021.156

18
[6]
Quartuccio and Rubello performed a comprehensive database review and meta-analysis of F-FDG
PET/CT for detection of hematogenous spread of metastatic differentiated thyroid cancer and found a
detection rate of 87% with specificity of 86%. This confirms the utility of this technique in the follow-up of
patients with metastatic DTC.

Corn et al. review the issue of finding uptake in the thyroid when F-FDG PET/CT is performed for
[7]
18
evaluation of other malignancies. They report incidental thyroid uptake on PET/CT at their institution in
3.4% of 4726 scans. Focal uptake was noted in 2.2%, and diffuse uptake was diffuse in 1.2%. They review the
literature and provide insightful recommendations for the management of the incidentaloma.

Matrone et al. provide a thorough review of the scientific rationale and current therapy of metastatic
[8]
medullary thyroid cancer.

Many patients with metastatic thyroid cancer are elderly and have cardiovascular disease that limits the
choice of therapy for the metastases. Izkhakov et al. review the influence of cardiovascular disease in the
[9]
overall prognosis among thyroid cancer survivors.

Damage to the recurrent laryngeal nerve is a major issue in the surgical treatment of thyroid cancer,
[10]
especially in regard to second surgeries for removal of local metastases. Priya et al. provide a timely review
of the methods and techniques of intraoperative recurrent laryngeal nerve monitoring for the preservation
of the function of this key structure.

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013.
JAMA 2017;317:1338-48. DOI PubMed PMC
2. Harari A, Singh RK. Increased rates of advanced thyroid cancer in California. J Surg Res 2016;201:244-52. DOI PubMed
3. Davidson CD, Carr FE. Review of pharmacological inhibition of thyroid cancer metabolism. J Cancer Metastasis Treat 2021;7:45.
DOI